Apeloa Pharmaceutical's controlling subsidiary, Kangyu Pharmaceutical, has recently received the Drug Registration Certificate for Levocarnitine Oral Solution from the National Medical Products Administration. The drug is an oral solution with specifications including 10 ml:1 g and 10 ml:2 g, primarily used for the treatment of primary systemic carnitine deficiency and secondary carnitine deficiency caused by congenital metabolic abnormalities. The domestic market size in 2025 is estimated at approximately 40.67 million units, with sales of around 298 million yuan. In the first quarter of 2026, Apeloa Pharmaceutical achieved revenue of 2.447 billion yuan and net profit attributable to the parent company of 249 million yuan.
Apeloa Pharmaceutical Co LtdSubsidiary received drug registration certificate for Levocarnitine Oral Solution, enabling market entry.
Received drug registration certificate for Levocarnitine Oral Solution, enabling market entry.